Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614001273673
Ethics application status
Not yet submitted
Date submitted
20/11/2014
Date registered
4/12/2014
Date last updated
4/12/2014
Type of registration
Prospectively registered
Titles & IDs
Public title
Efficacy of the Power Sleep Oral Device in the Management of Snoring and Sleep Apnoea
Query!
Scientific title
In adults with sleep apnoea, is the Power Sleep oral device (compared to baseline) effective in managing snoring and sleep apnoea?
Query!
Secondary ID [1]
285712
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1164-3899
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sleep apnoea
293582
0
Query!
Snoring
293583
0
Query!
Condition category
Condition code
Respiratory
293866
293866
0
0
Query!
Sleep apnoea
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The Power Sleep device is a non-customised, self-fitted intra-oral mandibular advancement splint designed to manage snoring and mild sleep apnoea. The Power Sleep device will be used for a single night whilst in bed, while simultaneously linked to an overnight polysomnography sleep study device at the participant's own home. Adherence will be measured using a single-item question "On the night that you used the device, for how much of the night did you use the device?" with responses ranging on a four point likert scale consisting of o (did not use device), 1 (some of the night), 2 (most of the night), 3 (the entire night).
Query!
Intervention code [1]
290663
0
Treatment: Devices
Query!
Comparator / control treatment
Intervention compared to baseline measures
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
293653
0
Apnea Hypopnea Index, assessed by PSG (overnight polysomnography) sleep test.
Query!
Assessment method [1]
293653
0
Query!
Timepoint [1]
293653
0
At baseline (no device), and treatment (oral device) 1 week later.
Query!
Primary outcome [2]
293654
0
Mean minimum oxygen saturation (min SaO2), assessed by PSG (overnight polysomnography) sleep test.
Query!
Assessment method [2]
293654
0
Query!
Timepoint [2]
293654
0
At baseline (no device), and treatment (oral device) 1 week later.
Query!
Primary outcome [3]
293655
0
Snoring loudness (dB), assessed by PSG (overnight polysomnography) sleep test.
Query!
Assessment method [3]
293655
0
Query!
Timepoint [3]
293655
0
At baseline (no device), and treatment (oral device) 1 week later.
Query!
Secondary outcome [1]
311520
0
Snoring frequency (0-100%), assessed by PSG (overnight polysomnography) sleep test.
Query!
Assessment method [1]
311520
0
Query!
Timepoint [1]
311520
0
At baseline (no device), and treatment (oral device) 1 week later while wearing Power Sleep oral device.
Query!
Secondary outcome [2]
311521
0
Side effects (assessed by the Side-Effects Questionnaire and clinical assessment). This questionnaire is not validated, but was developed by collating the known side-effects of other existing oral devices used for sleep apnoea. Therefore, it will be accompanied by a clinical assessment to ascertain and record any additional or unexpected side-effects. Examples of possible side effects include: dry mouth, excessive salivation, temporomandibular symptoms (pain, clicking, limited opening), muscle spasm or stiffness, altered occlusion (bite), tooth pain, mobile teeth, broken teeth, biting of lips or cheeks mouth ulcers, periodontal problems, root resorption, muscle spasms, difficulty getting back to sleep after waking to go to toilet, issues with retention of device, and poor adherence.
Query!
Assessment method [2]
311521
0
Query!
Timepoint [2]
311521
0
Within 24 hours following sleep device intervention.
Query!
Secondary outcome [3]
311522
0
Comfort level (assessed by the Sleep Device Questionnaire)
Query!
Assessment method [3]
311522
0
Query!
Timepoint [3]
311522
0
Within 24 hours following sleep device intervention.
Query!
Secondary outcome [4]
311523
0
Adherence (assessed by the Sleep Device Questionnaire)
Query!
Assessment method [4]
311523
0
Query!
Timepoint [4]
311523
0
Within 24 hours following sleep device intervention.
Query!
Eligibility
Key inclusion criteria
Apnea Hypopnea Index-Total (AHI-total) score of five (5) or greater (assessed by overnight PSG home sleep study). This includes participants ranging from mild to severe in severity of sleep apnoea.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Unstable cardiovascular disease (untreated hypertension acceptable);
Upper or lower respiratory tract disease (e.g., upper respiratory tract infection, rhinitis, sinusitis, chronic obstructive pulmonary disease), including a history of nasal allergy;
Dental pathology such as infection, abscess in bone, tumour, cracked teeth, and severe dental decay;
Inability to tolerate oral device due to oral or psychological condition;
Pregnant/Breast Feeding;
Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as co-existent other sleep disorder, psychiatric disease, history of non-compliance to medical regimens, or unwillingness to comply with study requirements;
Known widespread allergy or hypersensitivity (Atopia).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants previously diagnosed with sleep apnoea within the last 15 years were invited to participate in the study. All participants meeting inclusion/exclusion criteria will be assigned to both baseline and intervention conditions.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
All participants meeting inclusion/exclusion criteria will be assigned to both baseline and intervention conditions.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Repeated measures t-test
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
8/12/2014
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
22/12/2014
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
290286
0
Government body
Query!
Name [1]
290286
0
Commercialisation Australia
Query!
Address [1]
290286
0
5th Floor, 111 Bourke Street, GPO Box 85, Melbourne, Victoria 3001
Query!
Country [1]
290286
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Associate Professor Jack Gerschman
Query!
Address
Melbourne Medical Centre, Suite 5, Level 3, 517 St Kilda Road, Melbourne, Victoria 3004
Query!
Country
Australia
Query!
Secondary sponsor category [1]
288999
0
Individual
Query!
Name [1]
288999
0
Joel Gerschman
Query!
Address [1]
288999
0
Melbourne Medical Centre, Suite 5, Level 3, 517 St Kilda Road, Melbourne, Victoria 3004
Query!
Country [1]
288999
0
Australia
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
291996
0
Bellberry Limited
Query!
Ethics committee address [1]
291996
0
129 Glen Osmond Road, Eastwood, South Australia 5063
Query!
Ethics committee country [1]
291996
0
Australia
Query!
Date submitted for ethics approval [1]
291996
0
19/11/2014
Query!
Approval date [1]
291996
0
Query!
Ethics approval number [1]
291996
0
Query!
Summary
Brief summary
Latest research demonstrates that up to 40 million Americans (17%), and 4 million Australians (17%) suffer from snoring and/or Obstructive Sleep Apnoea (Kryger, Roth, Rement Principles and Pracice of Sleep Medicine, 5th Ed.). Nevertheless, only a small percentage have received treatment (5% in America and less than 1% in Australia; American Society of Sleep Medicine, USA, 2014). Current treatments are costly, time-consuming and difficult to tolerate. The Power Sleep (PS) oral device is a non-customised, self-fitted intra-oral mandibular advancement splint designed to manage snoring and sleep apnoea. This product has the potential to deliver a clinically effective outcome while reducing cost and increasing comfort levels. The current study aims to examine the efficacy and safety of the Power Sleep (PS) oral device in the management of snoring and sleep apnoea. A pre-post test design involving measures at baseline and using the oral device will be employed using approximately 30 participants aged 18-65 with sleep apnoea. It is hypothesized that the Power Sleep (PS) oral device will have a salutatory effect compared to baseline measures on: (a) snoring loudness; (b) snoring frequency; (c) Apnoea Hypopnea Index-REM (AHI-REM); (d) Apnoea Hypopnea Index-Total (AHI-Total); and (e) mean minimum oxygen saturation (min SaO2).
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
52954
0
A/Prof Jack Gerschman
Query!
Address
52954
0
Melbourne Medical Centre, Suite 5, Level 3, 517 St Kilda Road, Melbourne, Victoria 3004.
Query!
Country
52954
0
Australia
Query!
Phone
52954
0
+61 3 9867 8522
Query!
Fax
52954
0
Query!
Email
52954
0
[email protected]
Query!
Contact person for public queries
Name
52955
0
A/Prof Jack Gerschman
Query!
Address
52955
0
Melbourne Medical Centre, Suite 5, Level 3, 517 St Kilda Road, Melbourne, Victoria 3004.
Query!
Country
52955
0
Australia
Query!
Phone
52955
0
+61 3 9867 8522
Query!
Fax
52955
0
Query!
Email
52955
0
[email protected]
Query!
Contact person for scientific queries
Name
52956
0
A/Prof Jack Gerschman
Query!
Address
52956
0
Melbourne Medical Centre, Suite 5, Level 3, 517 St Kilda Road, Melbourne, Victoria 3004.
Query!
Country
52956
0
Australia
Query!
Phone
52956
0
+61 3 9867 8522
Query!
Fax
52956
0
Query!
Email
52956
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Current supporting documents:
Updated to:
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
23367
Clinical study report
-999999
23368
Ethical approval
-999999
Results publications and other study-related documents
Documents added manually
Current Study Results
No documents have been uploaded by study researchers.
Update to Study Results
Doc. No.
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
3810
Basic results
No
367474-(Uploaded-21-11-2018-09-46-25)-Basic results summary.docx
3982
Plain language summary
No
The overall purpose of this study was to investiga...
[
More Details
]
Documents added automatically
No additional documents have been identified.
Download to PDF